Development and application of global assays of hyper‐ and hypofibrinolysis
Open Access
- 6 November 2019
- journal article
- research article
- Published by Elsevier in Research and Practice in Thrombosis and Haemostasis
- Vol. 4 (1) , 46-53
Abstract
No abstract availableKeywords
Funding Information
- Pfizer Foundation (ASPIRE WI227678)
- National Heart, Lung, and Blood Institute (1RO1HL146226, T32HL007149-35)
This publication has 34 references indexed in Scilit:
- The role of thrombin activatable fibrinolysis inhibitor in arterial thrombosis at a young age: the ATTAC studyJournal of Thrombosis and Haemostasis, 2009
- Plasminogen deficiencyHaemophilia, 2008
- Insights into abnormal hemostasis in the Quebec platelet disorder from analyses of clot lysisJournal of Thrombosis and Haemostasis, 2006
- A new functional assay of thrombin activatable fibrinolysis inhibitorJournal of Thrombosis and Haemostasis, 2005
- Overall hemostatic potential (OHP) assay—a possible tool for determination of prothrombotic pattern in FXII deficiencyJournal of Thrombosis and Haemostasis, 2004
- A new euglobulin clot lysis assay for global fibrinolysisThrombosis Research, 2003
- Complete Deficiency of Plasminogen-Activator Inhibitor Type 1 Due to a Frame-Shift MutationNew England Journal of Medicine, 1992
- A simple, large scale method for preparation of plasminogen-free fibrinogenThrombosis Research, 1972
- Methodological study and a recommended technique for determining the euglobulin lysis timeJournal of Clinical Pathology, 1968
- Automatic determination of euglobulin lysis timeJournal of Clinical Pathology, 1965